CompletedPhase 2

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

United States203 participantsStarted 2006-12

Plain-language summary

The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * major abscess requiring surgical incision and drainage,infected burn, deep/extensive cellulitis, infected ulcer, wound infections * requires at least 7 days of intravenous antibiotic treatment Exclusion Criteria: * more than 24 hours of antibiotic therapy * moderate or severe liver disease * severely neutropenic * baseline QTc \> 500 msec, congenital long QT syndrome, uncompensated heart failure, uncorrected abnormal K+ or Mg++ blood levels or severe left ventricular hypertrophy

What they're measuring

Clinical response

Timeframe: 7 to 14 days after last antibiotic dose

Trial details

NCT IDNCT00442832

SponsorTheravance Biopharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-05

View on ClinicalTrials.gov More Staphylococcal Skin Infection trials